Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin a-4 phosphate

Table 1 Demographics of the study subjects who were treated with intravenous combretastatin A-4 phosphate and characteristics of study and fellow eyes at baseline

Patient	Age	Gender	Race	Previous treatment	CNV SE	CNV FE	BCVA		FTH
Patient	Age	Gender	Race	Previous treatment	CNV SE	CNV FE	SE	FE	SE	FE
1	81	F	White	PDT × 3	Subfoveal occult	Disciform Scar*	60	25	187	127
2	82	F	Hispanic	PDT × 2	Subfoveal occult	Subfoveal occult disciform scar*	73	4	204	573
3	84	F	White	PDT × 2	Subfoveal occult	No CNV	64	80	404	183
4	57	M	White	PDT × 3	Subfoveal minimally classic	Extrafoveal active occult foveal disciform scar *	67	73	346	236
5	64	F	White	PDT × 4	Subfoveal occult with disciform scar	Disciform scar	30	PL	519	x
6	70	M	White	PDT × 2	Subfoveal minimally	Subfoveal occult*	72	47	366	256
7	75	F	White	PDT × 2	Subfoveal occult	No CNV	25	72	292	238
8	79	F	White	PDT × 3	Subfoveal occult	Subfoveal occult*	64	48	450	393
Mean (±SD)	74 (±9.6)						56.9 (18.7±)	49.9 (±27.9)	346.0 (±115.2)	286.6(±150.2)

The asterisks indicate the fellow eyes that had active CNV at baseline. CNV = Choroidal neovascular membrane; SE = Study Eye; FE = Fellow Eye, BCVA = Best corrected visual acuity; FTH = central foveal thickness; PDT = photodynamic therapy; M = Male; F = Female; SD = Standard deviation.

ISSN: 2050-6511